RPS6 and colorectal carcinoma: Collectively, these results demonstrate that pharmacologic inhibition of the S6K/RPS6 axis using LY2584702 suppresses LIN28B-driven cell migration and invasion in CRC cells, and combining PI3Kα inhibition with S6K inhibition may have an additive effect.